Superior Group of Companies (SGC) 10-Q 7 May 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2024	Apr. 24, 2024
Document Information [Line Items]
Entity Central Index Key	0000095574
Entity Registrant Name	SUPERIOR GROUP OF COMPANIES, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-05869
Entity Incorporation, State or Country Code	FL
Entity Tax Identification Number	11-1385670
Entity Address, Address Line One	200 Central Avenue, Suite 2000
Entity Address, City or Town	St. Petersburg
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33701
City Area Code	727
Local Phone Number	397-9611
Title of 12(b) Security	Common Stock $0.001 par value per share
Trading Symbol	SGC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		16,745,192

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net sales	$ 138,842	$ 130,773
Costs and expenses:
Cost of goods sold	83,525	83,665
Selling and administrative expenses	48,749	43,379
Other periodic pension costs	189	214
Interest expense	1,787	2,570
Costs and Expenses, Excluding Gain on Sale of Property Plant and Equipment	134,250	129,828
Income before income tax expense	4,592	945
Income tax expense	680	57
Net income	$ 3,912	$ 888
Net income per share:
Basic (in dollars per share)	$ 0.24	$ 0.06
Diluted (in dollars per share)	$ 0.24	$ 0.06
Weighted average shares outstanding during the period:
Weighted average number of shares outstanding during the period, basic (in shares)	16,028,032	15,882,994
Weighted average number of shares outstanding during the period, diluted (in shares)	16,453,452	16,118,329
Other comprehensive income (loss), net of tax:
Recognition of net losses included in net periodic pension costs	$ 23	$ 41
Foreign currency translation adjustment	(481)	307
Other comprehensive income (loss)	(458)	348
Comprehensive income	$ 3,454	$ 1,236
Cash dividends per common share (in dollars per share)	$ 0.14	$ 0.14

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 22,040	$ 19,896
Accounts receivable, less allowance for doubtful accounts of $4,213 and $4,237, respectively	93,737	103,494
Accounts receivable - other	119	307
Inventories	92,573	98,067
Contract assets	52,511	48,715
Prepaid expenses and other current assets	6,549	8,881
Total current assets	267,529	279,360
Property, plant and equipment, net	45,319	46,890
Operating lease right-of-use assets	17,484	17,909
Deferred tax asset	12,349	12,356
Intangible assets, net	50,150	51,160
Other assets	15,650	14,775
Total assets	408,481	422,450
Current liabilities:
Accounts payable	41,653	50,520
Other current liabilities	40,414	43,978
Current portion of long-term debt	5,156	4,688
Current portion of acquisition-related contingent liabilities	942	1,403
Total current liabilities	88,165	100,589
Long-term debt	84,445	88,789
Long-term pension liability	13,361	13,284
Long-term acquisition-related contingent liabilities	612	557
Long-term operating lease liabilities	12,513	12,809
Other long-term liabilities	8,564	8,784
Total liabilities	207,660	224,812
Commitments and contingencies (Note 5)
Shareholders’ equity:
Preferred stock, $.001 par value - authorized 300,000 shares (none issued)	0	0
Common stock, $.001 par value - authorized 50,000,000 shares, issued and outstanding 16,743,723 and 16,564,712 shares, respectively	16	16
Additional paid-in capital	79,602	77,443
Retained earnings	123,946	122,464
Accumulated other comprehensive loss, net of tax:
Pensions	(1,099)	(1,122)
Foreign currency translation adjustment	(1,644)	(1,163)
Total shareholders’ equity	200,821	197,638
Total liabilities and shareholders’ equity	$ 408,481	$ 422,450

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounts receivable, allowance for doubtful accounts	$ 4,213	$ 4,237
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	300,000	300,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	16,743,723	16,564,712
Common stock, shares outstanding (in shares)	16,743,723	16,564,712

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Restricted Stock [Member] Common Stock [Member]	Restricted Stock [Member] Additional Paid-in Capital [Member]	Restricted Stock [Member] Retained Earnings [Member]	Restricted Stock [Member] AOCI Attributable to Parent [Member]	Restricted Stock [Member]	Performance Shares [Member] Common Stock [Member]	Performance Shares [Member] Additional Paid-in Capital [Member]	Performance Shares [Member] AOCI Attributable to Parent [Member]	Performance Shares [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2022										16,376,683
Balance at Dec. 31, 2022										$ 16	$ 72,615	$ 122,979	$ (3,011)	$ 192,599
Common shares issued upon exercise of options and SARs, net (in shares)										4,604
Common shares issued upon exercise of options and SARs, net										$ 0	35	0	0	35
Restricted shares issued, net of forfeitures (in shares)	117,025
Restricted shares issued, net of forfeitures	$ 0	$ 0	$ 0	$ 0	$ 0
Share-based compensation expense										0	1,080	0	0	1,080
Cash dividends declared										0	0	(2,295)	0	(2,295)
Net income										0	0	888	0	888
Pensions, net of taxes										0	0	0	41	41
Change in currency translation adjustment, net of taxes										$ 0	0	0	307	307
Performance based shares issued (in shares)	117,025
Balance (in shares) at Mar. 31, 2023										16,498,312
Balance at Mar. 31, 2023										$ 16	73,730	121,572	(2,663)	$ 192,655
Balance (in shares) at Dec. 31, 2023										16,564,712				16,564,712
Balance at Dec. 31, 2023										$ 16	77,443	122,464	(2,285)	$ 197,638
Common shares issued upon exercise of options and SARs, net										0	549	(100)	0	449
Restricted shares issued, net of forfeitures (in shares)	115,804					9,896
Restricted shares issued, net of forfeitures	$ 0	$ 0	$ 0	$ 0	$ 0
Share-based compensation expense										0	1,015	0	0	1,015
Cash dividends declared										0	0	(2,330)	0	(2,330)
Net income										0	0	3,912	0	3,912
Pensions, net of taxes										0	0	0	23	23
Change in currency translation adjustment, net of taxes										$ 0	0	0	(481)	$ (481)
Common shares issued upon exercise of options and SARs, net (in shares)										53,311				53,042
Performance based shares issued (in shares)	115,804					9,896
Performance based shares issued						$ 0	$ 0	$ 0	$ 0
Written put options										$ 0	595	0	0	$ 595
Balance (in shares) at Mar. 31, 2024										16,743,723				16,743,723
Balance at Mar. 31, 2024										$ 16	$ 79,602	$ 123,946	$ (2,743)	$ 200,821

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash dividends declared, per share (in dollars per share)	$ 0.14	$ 0.14
Pensions, tax	$ 7	$ 14
Change in currency translation adjustment, tax	$ 0	$ 0

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 3,912	$ 888
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,252	3,388
Inventory write-downs	420	0
Provision for bad debts - accounts receivable	83	(97)
Share-based compensation expense	1,015	1,080
Change in fair value of acquisition-related contingent liabilities	152	(563)
Change in fair value of written put options	392	(442)
Changes in assets and liabilities, net of acquisition of businesses:
Accounts receivable	9,419	10,150
Accounts receivable - other	188	2,928
Contract assets	(3,835)	1,590
Inventories	5,010	2,807
Prepaid expenses and other current assets	2,252	2,403
Other assets	(803)	(657)
Accounts payable and other current liabilities	(12,122)	1,596
Long-term pension liability	108	209
Other long-term liabilities	4	(230)
Net cash provided by operating activities	9,447	25,050
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(675)	(2,114)
Net cash used in investing activities	(675)	(2,114)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from borrowings of debt	7,000	1,000
Repayment of debt	(10,937)	(12,938)
Payment of cash dividends	(2,330)	(2,295)
Payment of acquisition-related contingent liabilities	(557)	0
Proceeds received on exercise of stock options	449	35
Net cash used in financing activities	(6,375)	(14,198)
Effect of currency exchange rates on cash	(253)	140
Net increase in cash and cash equivalents	2,144	8,878
Cash and cash equivalents balance, beginning of period	19,896	17,722
Cash and cash equivalents balance, end of period	$ 22,040	$ 26,600

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1 : Description of business Superior Group of Companies, Inc. (together with its subsidiaries, “the Company,” “Superior,” “we,” “our,” or “us”) was organized in 1920 1922 1998, May 3, 2018, Superior’s Branded Products segment, primarily through its signature marketing brands BAMKO® and HPI®, produces and sells customized merchandising solutions, promotional products and branded uniform programs. Branded products are manufactured through third Superior’s Healthcare Apparel segment, primarily through its signature marketing brands Fashion Seal Healthcare®, Wink® and CID Resources, manufactures (through third Superior’s Contact Centers segment, through multiple The Office Gurus® entities, including subsidiaries in El Salvador, Belize, Jamaica, Dominican Republic and the United States (collectively, “TOG”), provides outsourced, nearshore business process outsourcing, contact and call-center support services to North American customers. Basis of presentation The accompanying unaudited condensed consolidated financial statements of Superior included herein have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") ("U.S." or "United States") and the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. Intercompany items have been eliminated in consolidation. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10 December 31, 2023 not The Company refers to the condensed consolidated financial statements collectively as “financial statements,” and individually as “statements of comprehensive income,” “balance sheets,” “statements of shareholders’ equity,” and “statements of cash flows” herein. Reclassifications The accompanying financial statements for the previous year contain certain reclassifications. Reclassifications only impact items within Note 9 no Written Put Options During the second 2022, twenty-four three March 31, 2024 480, Distinguishing Liabilities from Equity March 31, 2024 December 31, 2023, three March 31, 2024 2023, March 31, 2024 Recent Accounting Pronouncements We consider the applicability and impact of all Accounting Standard Updates (“ASUs”). ASUs not not Recently Issued Accounting Pronouncements Not In November 2023, 2023 07, "Segment Reporting (Topic 280 Improvements to Reportable Segment Disclosures" December 15, 2023, December 15, 2024. not In December 2023, 2023 09, "Income Taxes (Topic 740 Improvements to Income Tax Disclosures" December 15, 2024, January 1, 2025. not not

Note 2 - Inventories

Note 2 - Inventories	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	2 Inventories consisted of the following amounts (in thousands): March 31, December 31, 2024 2023 Finished goods $ 67,110 $ 72,370 Work in process 834 671 Raw materials 24,629 25,026 Inventories $ 92,573 $ 98,067

Note 3 - Long-term Debt

Note 3 - Long-term Debt	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Long-Term Debt [Text Block]	3 Debt consisted of the following (in thousands): March 31, December 31, 2024 2023 Credit Facilities: Revolving credit facility due August 2027 $ 22,000 $ 25,000 Term loan due August 2027 68,438 69,375 90,438 94,375 Less: Payments due within one year included in current liabilities 5,156 4,688 Debt issuance costs 837 898 Long-term debt less current maturities $ 84,445 $ 88,789 On August 23, 2022, August 2027 Obligations outstanding under the Credit Facilities accrue interest at a variable rate equal to the secured overnight financing rate ("SOFR") plus an adjustment between 0.10% and 0.25% (depending on the applicable interest period) plus a margin between 1.0% and 2.0% (depending on the Company’s net leverage ratio). The weighted average interest rate on our outstanding borrowings under the Credit Facilities was 6.6% as of March 31, 2024 March 31, 2024 Contractual principal payments for the term loan are as follows: remainder of 2024 2025 2026 2027 not The Credit Facilities are secured by substantially all of the operating assets of the Company, and the Company’s obligations under the Credit Facilities are guaranteed by all of its domestic subsidiaries. The Company’s obligations under the Credit Facilities are subject to acceleration upon the occurrence of an event of default as defined in the Credit Agreement. The Credit Agreement contains customary events of default and negative covenants, including but not 1.0 not 1.0. four March 31, 2024

Note 4 - Net Sales

Note 4 - Net Sales	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4 For our Branded Products and Healthcare Apparel segments, revenue is primarily generated from the sale of finished products to customers. Revenues for our Branded Products and Healthcare Apparel segments are recognized when the performance obligations under the contract terms are satisfied. For certain contracts with customers in which the Company has an enforceable right to payment for goods with no not For our Contact Centers segment, revenue is generated from providing our customers with contact center services. Revenue for our Contact Centers segment is recognized as services are delivered. Revenue is measured at the amount of consideration we expect to receive in exchange for the goods or services. Variable consideration for estimated returns, allowances and other price variances is recorded based upon historical experience and current allowance programs. Contract terms may not not one one For further information regarding our net sales disaggregated by reportable segment see Note 9 Contract Assets and Contract Liabilities The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers (in thousands): March 31, December 31, 2024 2023 Accounts receivable $ 93,737 $ 103,494 Current contract assets 52,511 48,715 Current contract liabilities 5,780 5,346 Contract assets relate to goods produced without an alternative use for which the Company has an enforceable right to payment but which has not December 31, 2023 three March 31, 2024 three March 31, 2024 December 31, 2023

Note 5 - Contingencies

Note 5 - Contingencies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	5 – Contingencies: The purchase price to acquire substantially all of the assets of Sutter’s Mill Specialties, Inc. (“Sutter’s Mill”) in December 2021 2022 2024. July 2023, first 2024. May 2022 April 2025. March 31, 2024 third 2024. may may The Company is involved in various legal actions and claims arising from the normal course of business. In the opinion of management, the ultimate outcome of these matters is not

Note 6 - Share-based Compensati

Note 6 - Share-based Compensation	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	6 : Share-based compensation expense is recorded in selling and administrative expense in the statements of comprehensive income. The following table details the share-based compensation expense by type of award for the periods presented (in thousands): Three Months Ended March 31, 2024 2023 Stock options and SARs $ 268 $ 309 Restricted stock 654 590 Performance shares 93 181 Total share-based compensation expense $ 1,015 $ 1,080 Stock Options and Stock Appreciation Rights (“SARs”) The Company grants stock options and stock-settled SARs to employees that allow them to purchase shares of the Company’s common stock. Stock options are also granted to outside members of the Board of Directors of the Company. The Company determines the fair value of stock options and SARs at the date of grant using the Black-Scholes valuation model. All stock options and SARs vest between one three five ten 2013 “2013 2022 “2022 A summary of stock option transactions during the three March 31, 2024 Weighted Average Aggregate No. of Weighted Average Remaining Life Intrinsic Value Shares Exercise Price (in years) (in thousands) Outstanding, January 1, 2024 953,176 $ 14.73 2.80 $ 1,718 Granted (1) 167,300 13.84 Exercised (53,042 ) 10.23 Lapsed or cancelled (136,527 ) 17.18 Outstanding, March 31, 2024 930,907 14.47 3.41 3,311 Exercisable, March 31, 2024 407,366 17.36 2.20 1,009 ( 1 The weighted average grant date fair value of stock options granted was $13.84 per share. As of March 31, 2024 A summary of stock-settled SARs transactions during the three March 31, 2024 Weighted Average Aggregate No. of Weighted Average Remaining Life Intrinsic Value Shares Exercise Price (in years) (in thousands) Outstanding, January 1, 2024 292,508 $ 14.35 2.07 $ 506 Granted (1) 79,128 13.84 Exercised (17,920 ) 8.48 Lapsed or cancelled (54,064 ) 21.14 Outstanding, March 31, 2024 299,652 13.34 2.89 1,159 Exercisable, March 31, 2024 149,492 13.96 1.41 587 ( 1 The weighted average grant date fair value of SARs granted was $13.84 per share. As of March 31, 2024 Restricted Stock The Company has granted shares of restricted stock to directors and certain employees, which vest at a specified future date, generally after three five 2013 2022 A summary of restricted stock transactions during the three March 31, 2024 Weighted Average No. of Grant Date Shares Fair Value Outstanding, January 1, 2024 428,366 $ 18.14 Granted 115,804 13.84 Vested (13,039 ) 25.78 Forfeited - - Outstanding, March 31, 2024 531,131 17.01 As of March 31, 2024 Performance Shares The Company has granted performance shares, which either contain only service-based vesting conditions or service-based and performance-based vesting conditions. The service-based awards vest after the service period is met, which is generally three five five 2013 2022 A summary of performance share transactions during the three March 31, 2024 Weighted Average No. of Grant Date Shares Fair Value Outstanding, January 1, 2024 283,521 $ 18.13 Granted - - Vested (14,068 ) 17.77 Forfeited - - Outstanding, March 31, 2024 269,453 18.15 As of March 31, 2024

Note 7 - Income Taxes

Note 7 - Income Taxes	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7 – Income Taxes: The Company calculates its interim income tax provision in accordance with the accounting guidance for income taxes in interim periods. At the end of each interim period, the Company makes its best estimate of the annual expected effective tax rate and applies that rate to its ordinary year-to-date income or loss. The tax expense or benefit related to significant, unusual, or extraordinary items that will be separately reported or reported net of their related tax effect are individually computed and recognized in the interim period in which those items occur. The computation of the annual expected effective tax rate at each interim period requires certain estimates and assumptions including, but not may For the three March 31, 2024 three March 31, 2024 For the three March 31, 2023 three March 31, 2023

Note 8 - Net Income Per Share

Note 8 - Net Income Per Share	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	8 – Net Income Per Share: The Company’s basic net income per share is computed based on the weighted average number of shares of common stock outstanding for the period. Diluted net income per share includes the effect of the Company’s outstanding stock options, stock appreciation rights, nonvested shares of restricted stock and nonvested performance shares, if the inclusion of these items is dilutive. The following table presents a reconciliation of basic and diluted net income per share for the periods presented: Three Months Ended March 31, 2024 2023 Net income used in the computation of basic and diluted net income per share (in thousands) $ 3,912 $ 888 Weighted average shares outstanding - basic 16,028,032 15,882,994 Dilutive common stock equivalents 425,420 235,335 Weighted average shares outstanding - diluted 16,453,452 16,118,329 Net income per share: Basic $ 0.24 $ 0.06 Diluted $ 0.24 $ 0.06 Awards to purchase 400,075 and 1,008,972 shares of common stock with weighted average exercise prices of $20.86 and $17.03 per share were outstanding during the three March 31, 2024 2023 not

Note 9 - Operating Segment Info

Note 9 - Operating Segment Information	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	OTE 9 – Operating Segment Information : The Company manages and reports the following segments: Branded Products segment: Healthcare Apparel segment: third Contact Centers: Intersegment eliminations include the elimination of revenues and costs from services provided by the Contact Centers segment to the Company’s two not During the fourth 2023, The following tables set forth financial information related to the Company’s operating segments (in thousands): Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total As of and For the Three Months Ended March 31, 2024: Net sales $ 87,068 $ 29,237 $ 23,552 $ (1,015 ) $ - $ 138,842 Segment EBITDA 9,947 2,635 2,946 - (5,897 ) $ 9,631 Supplemental information: Depreciation and amortization $ 1,500 $ 937 $ 723 $ - $ 92 $ 3,252 Capital expenditures $ 265 $ 173 $ 160 $ - $ 77 $ 675 Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total As of and For the Three Months Ended March 31, 2023: Net sales $ 81,851 $ 28,154 $ 22,056 $ (1,288 ) $ - $ 130,773 Segment EBITDA 7,510 1,572 2,793 - (4,972 ) 6,903 Supplemental information: Depreciation and amortization $ 1,664 $ 974 $ 668 $ - $ 82 $ 3,388 Capital expenditures $ 1,271 $ 462 $ 381 $ - $ - $ 2,114 The following table reconciles income before income tax expense to Segment EBITDA (in thousands): Three Months Ended March 31, 2024 2023 Income before income tax expense $ 4,592 $ 945 Interest expense 1,787 2,570 Depreciation and amortization 3,252 3,388 Segment EBITDA $ 9,631 $ 6,903

Note 10 - Subsequent Events

Note 10 - Subsequent Events	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	10 – Subsequent Events : On May 1, 2024, 2022 May 6, 2024. one four January 1, 2024, thirty 30 May 10, 2024 12

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	5. Other On May 1, 2024 approved 125,000 75,000 Michael Benstock Michael Koempel 2022 May 6, 2024. one four January 1, 2024, thirty 30 May 10, 2024 115%, 130%, 150% twelve 12
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Adopted [Flag]	false

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, 2024 2023 Finished goods $ 67,110 $ 72,370 Work in process 834 671 Raw materials 24,629 25,026 Inventories $ 92,573 $ 98,067

Note 3 - Long-term Debt (Tables

Note 3 - Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	March 31, December 31, 2024 2023 Credit Facilities: Revolving credit facility due August 2027 $ 22,000 $ 25,000 Term loan due August 2027 68,438 69,375 90,438 94,375 Less: Payments due within one year included in current liabilities 5,156 4,688 Debt issuance costs 837 898 Long-term debt less current maturities $ 84,445 $ 88,789

Note 4 - Net Sales (Tables)

Note 4 - Net Sales (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Accounts Receivables and Contract Assets [Table Text Block]	March 31, December 31, 2024 2023 Accounts receivable $ 93,737 $ 103,494 Current contract assets 52,511 48,715 Current contract liabilities 5,780 5,346

Note 6 - Share-based Compensa_2

Note 6 - Share-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2024 2023 Stock options and SARs $ 268 $ 309 Restricted stock 654 590 Performance shares 93 181 Total share-based compensation expense $ 1,015 $ 1,080
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Aggregate No. of Weighted Average Remaining Life Intrinsic Value Shares Exercise Price (in years) (in thousands) Outstanding, January 1, 2024 953,176 $ 14.73 2.80 $ 1,718 Granted (1) 167,300 13.84 Exercised (53,042 ) 10.23 Lapsed or cancelled (136,527 ) 17.18 Outstanding, March 31, 2024 930,907 14.47 3.41 3,311 Exercisable, March 31, 2024 407,366 17.36 2.20 1,009
Share-Based Payment Arrangement, Stock Appreciation Right, Activity [Table Text Block]	Weighted Average Aggregate No. of Weighted Average Remaining Life Intrinsic Value Shares Exercise Price (in years) (in thousands) Outstanding, January 1, 2024 292,508 $ 14.35 2.07 $ 506 Granted (1) 79,128 13.84 Exercised (17,920 ) 8.48 Lapsed or cancelled (54,064 ) 21.14 Outstanding, March 31, 2024 299,652 13.34 2.89 1,159 Exercisable, March 31, 2024 149,492 13.96 1.41 587
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Average No. of Grant Date Shares Fair Value Outstanding, January 1, 2024 428,366 $ 18.14 Granted 115,804 13.84 Vested (13,039 ) 25.78 Forfeited - - Outstanding, March 31, 2024 531,131 17.01
Schedule of Nonvested Performance-Based Units Activity [Table Text Block]	Weighted Average No. of Grant Date Shares Fair Value Outstanding, January 1, 2024 283,521 $ 18.13 Granted - - Vested (14,068 ) 17.77 Forfeited - - Outstanding, March 31, 2024 269,453 18.15

Note 8 - Net Income Per Share (

Note 8 - Net Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2024 2023 Net income used in the computation of basic and diluted net income per share (in thousands) $ 3,912 $ 888 Weighted average shares outstanding - basic 16,028,032 15,882,994 Dilutive common stock equivalents 425,420 235,335 Weighted average shares outstanding - diluted 16,453,452 16,118,329 Net income per share: Basic $ 0.24 $ 0.06 Diluted $ 0.24 $ 0.06

Note 9 - Operating Segment In_2

Note 9 - Operating Segment Information (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total As of and For the Three Months Ended March 31, 2024: Net sales $ 87,068 $ 29,237 $ 23,552 $ (1,015 ) $ - $ 138,842 Segment EBITDA 9,947 2,635 2,946 - (5,897 ) $ 9,631 Supplemental information: Depreciation and amortization $ 1,500 $ 937 $ 723 $ - $ 92 $ 3,252 Capital expenditures $ 265 $ 173 $ 160 $ - $ 77 $ 675 Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total As of and For the Three Months Ended March 31, 2023: Net sales $ 81,851 $ 28,154 $ 22,056 $ (1,288 ) $ - $ 130,773 Segment EBITDA 7,510 1,572 2,793 - (4,972 ) 6,903 Supplemental information: Depreciation and amortization $ 1,664 $ 974 $ 668 $ - $ 82 $ 3,388 Capital expenditures $ 1,271 $ 462 $ 381 $ - $ - $ 2,114
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Three Months Ended March 31, 2024 2023 Income before income tax expense $ 4,592 $ 945 Interest expense 1,787 2,570 Depreciation and amortization 3,252 3,388 Segment EBITDA $ 9,631 $ 6,903

Note 1 - Description of Busin_2

Note 1 - Description of Business and Basis of Presentation (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Jun. 30, 2022
Unrealized Gain (Loss) on Derivatives	$ (392)	$ 442
Options Held [Member]
Derivative, Underlying Investment, Shares (in shares)	95,400			207,970
Derivative, Underlying Investment, Fair Value	$ 1,600		$ 1,800	$ 3,600
Open Option Contracts, Expiration Period (Month)				24 months
Derivative, Underlying Investment, Shares, Expirations in Period (in shares)	37,524
Increase (Decrease) in Derivative Liabilities	$ (600)
Unrealized Gain (Loss) on Derivatives	$ (400)	$ 400

Note 2 - Inventories - Inventor

Note 2 - Inventories - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Finished goods	$ 67,110		$ 72,370
Work in process	834		671
Raw materials	24,629		25,026
Inventories	$ 92,573	$ 98,067	$ 98,067

Note 3 - Long-term Debt (Detail

Note 3 - Long-term Debt (Details Textual) - Credit Agreement [Member] $ in Thousands	Aug. 23, 2022 USD ($)	Mar. 31, 2024 USD ($)
Long-Term Debt, Maturity, Remainder of Fiscal Year		$ 3,800
Long-Term Debt, Maturity, Year One		5,600
Long-Term Debt, Maturity, Year Two		6,600
Long-Term Debt, Maturity, Year Three		$ 52,400
Debt Instrument Covenant Fixed Charge Coverage Ratio	1.25
Debt Instrument Covenant, Net Leverage Ratio	4
PNC Bank [Member]
Line of Credit Facility, Additional Capacity Available	$ 75,000
Debt, Weighted Average Interest Rate		6.60%
PNC Bank [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.10%
PNC Bank [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.25%
PNC Bank [Member] | Adjusted Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1%
PNC Bank [Member] | Adjusted Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	2%
Revolving Credit Facility [Member]
Letters of Credit Outstanding, Amount		$ 0
Revolving Credit Facility [Member] | PNC Bank [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 125,000
Revolving Credit Facility [Member] | PNC Bank [Member] | Minimum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.125%
Revolving Credit Facility [Member] | PNC Bank [Member] | Maximum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Term Loan [Member] | PNC Bank [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 75,000

Note 3 - Long-term Debt - Long-

Note 3 - Long-term Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Long-term debt, gross	$ 90,438		$ 94,375
Payments due within one year included in current liabilities	5,156		4,688
Debt issuance costs	837		898
Long-term debt less current maturities	84,445	$ 88,789	88,789
PNC Bank [Member] | Revolving Credit Facility [Member]
Long-term debt, gross	22,000		25,000
BB&T [Member] | Term Loan Maturing May 2020 [Member]
Long-term debt, gross	$ 68,438		$ 69,375

Note 4 - Net Sales (Details Tex

Note 4 - Net Sales (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Contract with Customer, Liability, Revenue Recognized	$ 2

Note 4 - Net Sales - Accounts R

Note 4 - Net Sales - Accounts Receivable and Contract Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Accounts receivable	$ 93,737	$ 103,494	$ 103,494
Current contract assets	52,511	$ 48,715	48,715
Current contract liabilities	$ 5,780		$ 5,346

Note 5 - Contingencies (Details

Note 5 - Contingencies (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Business Combination, Contingent Consideration, Liability, Current		$ 942	$ 1,403
Sutter's Mill [Member]
Business Combination, Contingent Consideration, Liability, Current		500
Guardian Products, Inc [Member]
Business Combination, Contingent Consideration, Liability, Current		1,600
Guardian Products, Inc [Member] | Minimum [Member]
Business Combination, Contingent Consideration, Liability, Current		1,900
Guardian Products, Inc [Member] | Maximum [Member]
Business Combination, Contingent Consideration, Liability, Current		$ 2,200
Guardian Products, Inc [Member] | Forecast [Member]
Business Combination, Contingent Consideration, Liability, Current	$ 900

Note 6 - Share-based Compensa_3

Note 6 - Share-based Compensation (Details Textual) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	5 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 13.84
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 1.2
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 4 months 24 days
Stock Appreciation Rights (SARs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 0.4
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 6 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 13.84
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 4.8
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 9 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 13.84
Performance Shares [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 1
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 4 months 24 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 0
Outside Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year
Minimum [Member] | Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Maximum [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	5 years
Maximum [Member] | Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	5 years

Note 6 - Share-based Compensa_4

Note 6 - Share-based Compensation - Shared-based Compensation Expense and the Related Tax Benefit (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based compensation expense	$ 1,015	$ 1,080
Stock Options and SARs [Member]
Share-based compensation expense	268	309
Restricted Stock [Member]
Share-based compensation expense	654	590
Performance Shares [Member]
Share-based compensation expense	$ 93	$ 181

Note 6 - Share-based Compensa_5

Note 6 - Share-based Compensation - Stock Option Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Outstanding, options (in shares)	953,176
Outstanding, weighted average exercise price (in dollars per share)	$ 14.73
Outstanding, weighted average remaining life (Year)	3 years 4 months 28 days	2 years 9 months 18 days
Outstanding, aggregate intrinsic value	$ 3,311	$ 1,718
Granted (in shares)	167,300
Granted, weighted average exercise price (in dollars per share)	$ 13.84
Exercised (in shares)	(53,042)
Exercised, weighted average exercise price (in dollars per share)	$ 10.23
Lapsed or cancelled (in shares)	(136,527)
Lapsed or cancelled, weighted average exercise price (in dollars per share)	$ 17.18
Outstanding, options (in shares)	930,907	953,176
Outstanding, weighted average exercise price (in dollars per share)	$ 14.47	$ 14.73
Exercisable, options (in shares)	407,366
Exercisable, weighted average exercise price, options (in dollars per share)	$ 17.36
Exercisable, weighted average remaining life (Year)	2 years 2 months 12 days
Exercisable, aggregate intrinsic value, options	$ 1,009

Note 6 - Share-based Compensa_6

Note 6 - Share-based Compensation - Stock-settled Stock Appreciation Rights Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Lapsed or cancelled (in shares)	(136,527)
Lapsed or cancelled, weighted average exercise price (in dollars per share)	$ 17.18
Stock Appreciation Rights (SARs) [Member]
Outstanding SARS (in shares)	292,508
Outstanding (in dollars per share)	$ 14.35
Outstanding SARS, weighted average remaining life (Year)	2 years 10 months 20 days	2 years 25 days
Outstanding SARS, aggregate intrinsic value	$ 1,159	$ 506
Granted SARs (in shares)	79,128
Granted SARS, weighted average exercise price (in dollars per share)	$ 13.84
Exercised SARs (in shares)	(17,920)
Exercised SARS, weighted average exercise price (in dollars per share)	$ 8.48
Lapsed or cancelled (in shares)	(54,064)
Lapsed or cancelled, weighted average exercise price (in dollars per share)	$ 21.14
Outstanding SARS (in shares)	299,652	292,508
Outstanding SARS, weighted average exercise price (in dollars per share)	$ 13.34	$ 14.35
Exercisable (in shares)	149,492
Exercisable, weighted average exercise price (in dollars per share)	$ 13.96
Exercisable SARS, weighted average remaining life (Year)	1 year 4 months 28 days
Exercisable, aggregate intrinsic value	$ 587

Note 6 - Share-based Compensa_7

Note 6 - Share-based Compensation - Restricted Stock Transactions (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Outstanding (in shares) | shares	428,366
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 18.14
Granted (in shares) | shares	115,804
Granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 13.84
Vested (in shares) | shares	(13,039)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 25.78
Forfeited (in shares) | shares	0
Forfeited, weighted average grant date fair value (in dollars per share) | $ / shares	$ 0
Outstanding (in shares) | shares	531,131
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 17.01

Note 6 - Share-based Compensa_8

Note 6 - Share-based Compensation - Performance Share Transactions (Details) - Performance Shares [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Outstanding (in shares) | shares	283,521
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 18.13
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | shares	0
Granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 0
Vested (in shares) | shares	(14,068)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 17.77
Forfeited (in shares) | shares	0
Forfeited, weighted average grant date fair value (in dollars per share) | $ / shares	$ 0
Outstanding (in shares) | shares	269,453
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 18.15

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Expense (Benefit)	$ 680	$ 57
Effective Income Tax Rate Reconciliation, Percent	14.80%	6%
Supplemental Executive Retirement Plan (SERP) [Member]
Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount		$ 200
Put Option [Member]
Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount		$ 400

Note 8 - Net Income Per Share_2

Note 8 - Net Income Per Share (Details Textual) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	400,075	1,008,972
Antidilutive Securities Excluded from Computation of Earnings Per Share, Weight Average Exercise Price (in dollars per share)	$ 20.86	$ 17.03

Note 8 - Net Income Per Share -

Note 8 - Net Income Per Share - Reconciliation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net income	$ 3,912	$ 888
Weighted average shares outstanding - basic (in shares)	16,028,032	15,882,994
Dilutive common stock equivalents (in shares)	425,420	235,335
Weighted average shares outstanding - diluted (in shares)	16,453,452	16,118,329
Basic (in dollars per share)	$ 0.24	$ 0.06
Diluted (in dollars per share)	$ 0.24	$ 0.06

Note 9 - Operating Segment In_3

Note 9 - Operating Segment Information - Information Related to the Operations of the Company's Operating Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net sales	$ 138,842	$ 130,773
Segment EBITDA	9,631	6,903
Depreciation and amortization	3,252	3,388
Capital expenditures	675	2,114
Depreciation and amortization	3,252	3,388
Operating Segments [Member] | Branded Products [Member]
Net sales	87,068	81,851
Segment EBITDA	9,947	7,510
Depreciation and amortization	1,500	1,664
Capital expenditures	265	1,271
Depreciation and amortization	1,500	1,664
Operating Segments [Member] | Healthcare Apparel [Member]
Net sales	29,237	28,154
Segment EBITDA	2,635	1,572
Depreciation and amortization	937	974
Capital expenditures	173	462
Depreciation and amortization	937	974
Operating Segments [Member] | Contact Centers [Member]
Net sales	23,552	22,056
Segment EBITDA	2,946	2,793
Depreciation and amortization	723	668
Capital expenditures	160	381
Depreciation and amortization	723	668
Intersegment Eliminations [Member]
Net sales	(1,015)	(1,288)
Segment EBITDA	0	0
Depreciation and amortization	0	0
Capital expenditures	0	0
Depreciation and amortization	0	0
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]
Net sales	0	0
Segment EBITDA	(5,897)	(4,972)
Depreciation and amortization	92	82
Capital expenditures	77	0
Depreciation and amortization	$ 92	$ 82

Note 9 - Operating Segment In_4

Note 9 - Operating Segment Information - Segment Adjusted EBITDA Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income before income tax expense	$ 4,592	$ 945
Interest expense	1,787	2,570
Depreciation and amortization	3,252	3,388
Segment EBITDA	$ 9,631	$ 6,903

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - Performance Shares [Member] - shares			3 Months Ended
	May 06, 2024	Apr. 01, 2024	Mar. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			0
Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		4 years
Subsequent Event [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage over VWAP		115%
Subsequent Event [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage over VWAP		130%
Subsequent Event [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage over VWAP		150%
Subsequent Event [Member] | Share-Based Payment Arrangement, Tranche Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage over VWAP		12%
Subsequent Event [Member] | Share-Based Payment Arrangement, Tranche Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage over VWAP		12%
Subsequent Event [Member] | Michael Benstock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	125,000
Subsequent Event [Member] | Michael Koempel [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	75,000